| Autor: |
Jonny G. Peter, MB ChB, MMed, FCP (SA), PhD, Bhavisha Desai, PharmD, Dianne Tomita, MPH, Phil Collis, PhD, Marcin Stobiecki, MD, PhD |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
World Allergy Organization Journal, Vol 16, Iss 11, Pp 100841- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1939-4551 |
| DOI: |
10.1016/j.waojou.2023.100841 |
| Popis: |
Background: Given the recent approval of oral berotralstat in several countries for hereditary angioedema (HAE) prophylaxis, transition from long-term androgens to berotralstat may occur in clinical practice. The open-label, Phase II APeX-S trial provided an opportunity to assess the safety and effectiveness of berotralstat in patients previously treated with differing durations of androgens and shorter transition periods. Therefore, we examined the safety, effectiveness, and impact on quality of life of berotralstat after prior androgen use in patients from the APeX-S trial. Alanine aminotransferase (ALT) elevations were also examined because of the association with androgen exposure and hepatic function impairment. Methods: We conducted an analysis of a subset of 39 patients from the APeX-S trial aged ≥12 years with HAE due to C1 inhibitor deficiency (HAE-C1-INH) with prior androgen use who discontinued androgen therapy within |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
